Johnson & Johnson (JNJ) Enterprise Value (EV): $532.30B
The enterprise value (EV) for Johnson & Johnson (JNJ) is $532.30B as of Wednesday, June 10, 2026.
JNJ Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$532.30B
JNJ Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Johnson & Johnson (JNJ) | — | $532.30B |
| Pfizer Inc. (PFE) | $146.36B | $207.77B |
| Merck & Co., Inc. (MRK) | $293.02B | $299.33B |
| AbbVie Inc. (ABBV) | $399.54B | $470.64B |
| Eli Lilly and Company (LLY) | $1.07T | $1.00T |
| Bristol-Myers Squibb Company (BMY) | $115.34B | $147.02B |
Enterprise Value Calculation
Market Cap
$574.15B
Total Debt
$47.93B
Cash
$19.71B
Enterprise Value
$532.30B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
Johnson & Johnson Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for Johnson & Johnson (JNJ)?
- The enterprise value (EV) for JNJ stock is $532.30B.
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato